3-溴-N,N-二乙基丙氨氢溴酸盐 | 69835-35-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 3-溴-N,N-二乙基丙氨氢溴酸盐
• 英文名称: 3-diethylamino-propyl bromide hydrobromide
• 英文别名: 3-bromopropyldiethylamine hydrobromide；diethyl-(3-bromo-propyl)-amine; hydrobromide；Diaethyl-(3-brom-propyl)-amin; Hydrobromid；Diaethyl-(3-brom-propyl)-ammonium-bromid；Diaethyl-(3-brom-propyl)-amin-hydrobromid；dipropylaminoethyl bromide hydrobromide；(3-Bromopropyl)diethylamine hydrobromide；3-bromo-N,N-diethylpropan-1-amine;hydrobromide
• CAS: 69835-35-4
• 化学式: BrH*C₇H₁₆BrN
• mdl: MFCD11109989
• 分子量: 275.027
• InChiKey: KAELPAFGRTUXOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.81
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921199090

反应信息

• 作为反应物：
  描述：

  3-溴-N,N-二乙基丙氨氢溴酸盐 在 盐酸 作用下， 生成 N²-(3-diethylamino-propyl)-benzothiazole-2,6-diyldiamine
  参考文献：
  名称：

  Tsuda et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1940, vol. 60, p. 462,473; dtsch. Ref. S. 184, 189

  摘要：

  DOI：
• 作为产物：
  描述：

  二乙基-(3-苯氧基-丙基)-胺 在 氢溴酸 作用下， 生成 3-溴-N,N-二乙基丙氨氢溴酸盐
  参考文献：
  名称：

  Marvel; Zartman; Bluthardt, Journal of the American Chemical Society, 1927, vol. 49, p. 2302

  摘要：

  DOI：

文献信息

• [EN] IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES<br/>[FR] LIPIDES AMINÉS IONISABLES ET NANOPARTICULES LIPIDIQUES
  申请人：INTELLIA THERAPEUTICS INC

  公开号：WO2020219876A1

  公开（公告）日：2020-10-29

  The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The ionizable amine lipids disclosed herein are useful as ionizable lipids in the formulation of lipid nanoparticle-based compositions.

  该披露提供了可离子化的胺脂质及其盐（例如，其药用可接受盐），用于传递生物活性剂，例如将生物活性剂传递到细胞中以制备工程细胞。本公开的可离子化胺脂质在脂质纳米粒子基础组合物的配方中作为可离子化脂质是有用的。
• Aminoindazole derivatives
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：US04533731A1

  公开（公告）日：1985-08-06

  A compound of the formula (I): ##STR1## wherein W.sub.1 and W.sub.2 each independently is a hydrogen atom or a ##STR2## group wherein Y is a n-C.sub.1-6 alkylene group or a n-C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.1 and R.sub.2 each independently is a hydrogen atom or a C.sub.1-6 alkyl group, and ##STR3## group in ##STR4## group may form a saturated heterocyclic ring selected from the group consisting of morpholino, pyrrolidino, piperidino, homopiperidino and piperazino groups, and the saturated heterocyclic ring except the morpholino group may have at least one C.sub.1-4 alkyl group, hydroxyl group or halogen atom as a substituent; Z.sub.1 is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxyl group, an amino group, a C.sub.1-3 alkyl group or a methoxy group; Z.sub.2 is a hydrogen atom or an amino group; when W.sub.1 and W.sub.2 are both hydrogen atoms, Z.sub.1 is a hydroxyl group or an iodine atom and Z.sub.2 is hydrogen atom, or Z.sub.1 and Z.sub.2 are both amino groups; when Z.sub.1 and Z.sub.2 are both hydrogen atoms, the ##STR5## group in either W.sub.1 or W.sub.2 is a morpholino group; when Z.sub.1 is a chlorine atom, a hydroxyl group, an iodine atom, a methyl group or a methoxy group, Z.sub.2 is a hydrogen atom; when Z.sub.1 is an amino group, Z.sub.2 is a hydrogen atom or an amino group; when Z.sub.1 is a methyl group, a methoxy group or an amino group, Z.sub.1 is in the 5-position; when Z.sub.1 is an iodine atom, Z.sub.1 is in the 5- or 7-position; and when Z.sub.1 and Z.sub.2 are both amino groups, Z.sub.1 and Z.sub.2 are in the 5- and 7-positions; and the physiologically acceptable acid addition salt thereof which compounds have pharmaceutical utility, e.g.: treating inflammation.

  式(I)的化合物：其中W.sub.1和W.sub.2各自独立地是氢原子或##STR2##基团，其中Y是n-C.sub.1-6烷基烯基或具有C.sub.1-6烷基基团取代物的n-C.sub.1-6烷基烯基；R.sub.1和R.sub.2各自独立地是氢原子或C.sub.1-6烷基基团，以及##STR3##在##STR4##基团中的基团可能形成从吗啡啉，吡咯啉，哌啶，环己哌啶和哌嗪基团中选择的饱和杂环环；除了吗啡啉基团之外的饱和杂环环可能具有至少一个C.sub.1-4烷基基团，羟基基团或卤原子作为取代物；Z.sub.1是氢原子，氯原子，溴原子，碘原子，羟基，氨基，C.sub.1-3烷基基团或甲氧基基团；Z.sub.2是氢原子或氨基；当W.sub.1和W.sub.2都是氢原子时，Z.sub.1是羟基或碘原子，Z.sub.2是氢原子，或Z.sub.1和Z.sub.2都是氨基；当Z.sub.1和Z.sub.2都是氢原子时，W.sub.1或W.sub.2中的##STR5##基团是吗啡啉基团；当Z.sub.1是氯原子，羟基，碘原子，甲基基团或甲氧基基团时，Z.sub.2是氢原子；当Z.sub.1是氨基时，Z.sub.2是氢原子或氨基；当Z.sub.1是甲基基团，甲氧基基团或氨基时，Z.sub.1在5-位；当Z.sub.1是碘原子时，Z.sub.1在5-位或7-位；当Z.sub.1和Z.sub.2都是氨基时，Z.sub.1和Z.sub.2在5-位和7-位；以及其生理上可接受的酸盐，这些化合物具有药用价值，例如：用于治疗炎症。
• Imidazoisoquinoline-diones and salts thereof
  申请人：Boehringer Ingelheim GmbH

  公开号：US04176184A1

  公开（公告）日：1979-11-27

  Compounds of the formula ##STR1## wherein R.sub.1 is lower alkyl; phenyl-lower alkyl; cycloalkyl of 3 to 6 carbon atoms; phenyl; mono- or di-substituted phenyl, where the substituents, which may be identical to or different from each other, are each halogen, hydroxyl, methoxy, methylmercapto, methylsulfinyl, methylsulfonyl or benzyloxy; and A is hydrogen or ##STR2## where R.sub.2 is hydrogen or lower alkyl; R.sub.3 is lower alkyl or dimethoxyphenyl-lower alkyl; or R.sub.2 and R.sub.3, together with each other and the nitrogen atom to which they are attached, are piperidino, morpholino or N'-lower alkyl-piperazino; and n is 2 or 3; and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as cardiotonics, hypotensives, antithrombotics and antiarrhythmics.

  式为##STR1##的化合物，其中R.sub.1为较低的烷基；苯基-较低的烷基；3至6个碳原子的环烷基；苯基；单取代或双取代的苯基，取代基可以相同也可以不同，每个取代基都是卤素、羟基、甲氧基、甲硫氧基、甲砜基或苄氧基；A为氢或##STR2##，其中R.sub.2为氢或较低的烷基；R.sub.3为较低的烷基或二甲氧基苯基-较低的烷基；或R.sub.2和R.sub.3，连同它们彼此和它们附着的氮原子，为哌啶基、吗啉基或N'-较低的烷基-哌嗪基；n为2或3；以及其非毒性、药理学上可接受的酸盐。这些化合物及其盐可用作心力衰竭药、降压药、抗血栓药和抗心律失常药。
• 3-Aminoindazole derivatives
  申请人：Asahi, Kasei, Kogyo, Kabushiki, Kaisha

  公开号：US04474964A1

  公开（公告）日：1984-10-02

  A compound of the formula (I): ##STR1## wherein W.sub.1 is a hydrogen atom or a ##STR2## group wherein Y is a C.sub.1-6 alkylene group or a C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.1 and R.sub.2 each independently is a hydrogen atom or a C.sub.1-6 alkyl group and R.sub.1 and R.sub.2 may form a C.sub.4-6 heterocyclic ring or a nitrogen-containing C.sub.4-6 heterocyclic ring together with the adjacent nitrogen atom and the C.sub.4-6 heterocyclic rings may have at least one C.sub.1-6 alkyl group, hydroxyl group or halogen atom; W.sub.2 is a hydrogen atom or a ##STR3## group wherein Z is a C.sub.1-6 alkylene group or a C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.3 and R.sub.4 each independently is a hydrogen atom or a C.sub.1-6 alkyl group and R.sub.3 and R.sub.4 may form a C.sub.4-6 heterocyclic ring or a nitrogen-containing C.sub.4-6 heterocyclic ring together with the adjacent nitrogen atom and the C.sub.4-6 heterocyclic rings may have at least one C.sub.1-6 alkyl group, hydroxyl group or halogen atom; when W.sub.1 is a hydrogen atom, W.sub.2 is the ##STR4## group; and when W.sub.2 is a hydrogen atom, W.sub.1 is the ##STR5## group; and the pharmaceutically acceptable acid addition salt thereof having antiinflammatory, analgesic and digestive tract ulcer suppressing activity.

  化合物的式子(I)：##STR1## 其中W.sub.1是氢原子或##STR2##基团，其中Y是C.sub.1-6烷基链或具有C.sub.1-6烷基链取代基的C.sub.1-6烷基链; R.sub.1和R.sub.2各自独立地是氢原子或C.sub.1-6烷基链，且R.sub.1和R.sub.2可以与相邻的氮原子一起形成C.sub.4-6杂环环或含氮的C.sub.4-6杂环环，且C.sub.4-6杂环环可以具有至少一个C.sub.1-6烷基链、羟基或卤原子；W.sub.2是氢原子或##STR3##基团，其中Z是C.sub.1-6烷基链或具有C.sub.1-6烷基链取代基的C.sub.1-6烷基链; R.sub.3和R.sub.4各自独立地是氢原子或C.sub.1-6烷基链，且R.sub.3和R.sub.4可以与相邻的氮原子一起形成C.sub.4-6杂环环或含氮的C.sub.4-6杂环环，且C.sub.4-6杂环环可以具有至少一个C.sub.1-6烷基链、羟基或卤原子；当W.sub.1是氢原子时，W.sub.2是##STR4##基团; 当W.sub.2是氢原子时，W.sub.1是##STR5##基团; 以及其药学上可接受的酸盐，具有抗炎、镇痛和消化道溃疡抑制活性。
• Indazole derivatives
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：US04751302A1

  公开（公告）日：1988-06-14

  A compound of the formula (I): ##STR1## wherein W.sub.1 and W.sub.2 each independently is a hydrogen atom or a ##STR2## wherein Y is a n-C.sub.1-6 alkylene group or a n-C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.1 and R.sub.2 each independently is a hydrogen atom or a C.sub.1-6 alkyl group, and ##STR3## may form a saturated heterocyclic ring selected from the group consisting of morpholino, pyrrolidino, piperidino, homopiperidino and piperazino groups, and the saturated heterocyclic ring except the morpholino group may have at least one C.sub.1-4 alkyl group, hydroxyl group or halogen atom as a substituent; Z.sub.1 is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxyl group, an amino group, a C.sub.1-3 alkyl group or a methoxy group; Z.sub.2 is a hydrogen atom or an amino group; when W.sub.1 and W.sub.2 are both hydrogen atoms, Z.sub.1 is a hydroxyl group or an iodine atom and Z.sub.2 is hydrogen atom, or Z.sub.1 and Z.sub.2 are both amino groups; when Z.sub.1 and Z.sub.2 are both hydrogen atoms, the ##STR4## in either W.sub.1 or W.sub.2 is a morpholino group; when Z.sub.1 is a chlorine atom, a hydroxyl group, an iodine atom, a methyl group or a methoxy group, Z.sub.2 is a hydrogen atom; when Z.sub.1 is an amino group, Z.sub.2 is a hydrogen atom or an amino group; when Z.sub.1 is a methyl group, a methoxy group or an amino group, Z.sub.1 is in the 5-position; when Z.sub.1 is an iodine atom, Z.sub.1 is in the 5- or 7-position; and when Z.sub.1 and Z.sub.2 are both amino groups, Z.sub.1 and Z.sub.2 are in the 5- and 7-positions; and the physiologically acceptable acid addition salt thereof.

  化合物的公式（I）：##STR1## 其中W.sub.1和W.sub.2各自独立地是氢原子或##STR2##其中Y是n-C.sub.1-6烷基或具有C.sub.1-6烷基取代基的n-C.sub.1-6烷基；R.sub.1和R.sub.2各自独立地是氢原子或C.sub.1-6烷基，且##STR3##可以形成从吗啡啶，吡咯烷，哌啶，同哌啶和哌嗪基中选出的饱和杂环环，除吗啡啶基外的饱和杂环环可以具有至少一个C.sub.1-4烷基，羟基或卤原子作为取代基；Z.sub.1是氢原子，氯原子，溴原子，碘原子，羟基，氨基，C.sub.1-3烷基或甲氧基；Z.sub.2是氢原子或氨基；当W.sub.1和W.sub.2都是氢原子时，Z.sub.1是羟基或碘原子，Z.sub.2是氢原子，或者Z.sub.1和Z.sub.2都是氨基；当Z.sub.1和Z.sub.2都是氢原子时，W.sub.1或W.sub.2中的##STR4##是吗啡啶基；当Z.sub.1是氯原子，羟基，碘原子，甲基或甲氧基时，Z.sub.2是氢原子；当Z.sub.1是氨基时，Z.sub.2是氢原子或氨基；当Z.sub.1是甲基，甲氧基或氨基时，Z.sub.1在5位；当Z.sub.1是碘原子时，Z.sub.1在5位或7位；当Z.sub.1和Z.sub.2都是氨基时，Z.sub.1和Z.sub.2在5位和7位；以及其生理上可接受的酸加成盐。